Literature DB >> 28729415

An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.

Dina S Stepanova1, Galina Semenova2, Yin-Ming Kuo3, Andrew J Andrews3, Sylwia Ammoun4, C Oliver Hanemann4, Jonathan Chernoff5.   

Abstract

Neurofibromatosis type 2 (NF2) is an autosomal dominant disorder characterized by the development of multiple tumors in the central nervous system, most notably schwannomas, and meningiomas. Mutational inactivation of the NF2 gene encoding the protein Merlin is found in most sporadic and inherited schwannomas, but the molecular mechanisms underlying neoplastic changes in schwannoma cells remain unclear. We report here that Nf2-deficient cells display elevated expression levels of key enzymes involved in lipogenesis and that this upregulation is caused by increased activity of Torc1. Inhibition or knockdown of fatty acid synthase (FASN), the enzyme that catalyzes the formation of palmitic acid from malonyl-CoA, drove NF2-deficient cells into apoptosis. Treatment of NF2-mutant cells with agents that inhibit the production of malonyl-CoA reduced their sensitivity to FASN inhibitors. Collectively, these results suggest that the altered lipid metabolism found in NF2-mutant cells renders them sensitive to elevated levels of malonyl-CoA, as occurs following blockade of FASN, suggesting new targeted strategies in the treatment of NF2-deficient tumors. Cancer Res; 77(18); 5026-38. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28729415      PMCID: PMC5600854          DOI: 10.1158/0008-5472.CAN-16-2834

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  56 in total

1.  Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity.

Authors:  J N Thupari; M L Pinn; F P Kuhajda
Journal:  Biochem Biophys Res Commun       Date:  2001-07-13       Impact factor: 3.575

2.  ErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas.

Authors:  Zana K Ahmad; Carrie M Brown; Roberto A Cueva; Allen F Ryan; Joni K Doherty
Journal:  Otol Neurotol       Date:  2011-07       Impact factor: 2.311

3.  Inhibition of fatty acid synthetases by the antibiotic cerulenin.

Authors:  D Vance; I Goldberg; O Mitsuhashi; K Bloch
Journal:  Biochem Biophys Res Commun       Date:  1972-08-07       Impact factor: 3.575

4.  Inhibition of beta-ketoacyl-acyl carrier protein synthases by thiolactomycin and cerulenin. Structure and mechanism.

Authors:  A C Price; K H Choi; R J Heath; Z Li; S W White; C O Rock
Journal:  J Biol Chem       Date:  2000-10-24       Impact factor: 5.157

5.  Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization.

Authors:  Joseph L Kissil; Kristen C Johnson; Matthew S Eckman; Tyler Jacks
Journal:  J Biol Chem       Date:  2002-01-08       Impact factor: 5.157

6.  Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2.

Authors:  M Giovannini; E Robanus-Maandag; M van der Valk; M Niwa-Kawakita; V Abramowski; L Goutebroze; J M Woodruff; A Berns; G Thomas
Journal:  Genes Dev       Date:  2000-07-01       Impact factor: 11.361

Review 7.  Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?

Authors:  Ruth Lupu; Javier A Menendez
Journal:  Curr Pharm Biotechnol       Date:  2006-12       Impact factor: 2.837

8.  Enhanced antitumor activity of cerulenin combined with oxaliplatin in human colon cancer cells.

Authors:  Risa Shiragami; Soichiro Murata; Chihiro Kosugi; Tohru Tezuka; Masato Yamazaki; Atsushi Hirano; Yukino Yoshimura; Masato Suzuki; Kiyohiko Shuto; Keiji Koda
Journal:  Int J Oncol       Date:  2013-06-07       Impact factor: 5.650

9.  Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells.

Authors:  P D Pelton; L S Sherman; T A Rizvi; M A Marchionni; P Wood; R A Friedman; N Ratner
Journal:  Oncogene       Date:  1998-10-29       Impact factor: 9.867

10.  SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth.

Authors:  Thomas Porstmann; Claudio R Santos; Beatrice Griffiths; Megan Cully; Mary Wu; Sally Leevers; John R Griffiths; Yuen-Li Chung; Almut Schulze
Journal:  Cell Metab       Date:  2008-09       Impact factor: 27.287

View more
  9 in total

1.  Cell contact and Nf2/Merlin-dependent regulation of TEAD palmitoylation and activity.

Authors:  Nam-Gyun Kim; Barry M Gumbiner
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-01       Impact factor: 11.205

2.  Molecular and translational advances in meningiomas.

Authors:  Suganth Suppiah; Farshad Nassiri; Wenya Linda Bi; Ian F Dunn; Clemens Oliver Hanemann; Craig M Horbinski; Rintaro Hashizume; Charles David James; Christian Mawrin; Houtan Noushmehr; Arie Perry; Felix Sahm; Andrew Sloan; Andreas Von Deimling; Patrick Y Wen; Kenneth Aldape; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

3.  The evolution and multi-molecular properties of NF1 cutaneous neurofibromas originating from C-fiber sensory endings and terminal Schwann cells at normal sites of sensory terminations in the skin.

Authors:  Frank L Rice; George Houk; James P Wymer; Sara J C Gosline; Justin Guinney; Jianqiang Wu; Nancy Ratner; Michael P Jankowski; Salvo La Rosa; Marilyn Dockum; James R Storey; Steven L Carroll; Phillip J Albrecht; Vincent M Riccardi
Journal:  PLoS One       Date:  2019-05-20       Impact factor: 3.752

4.  Peroxynitrite supports a metabolic reprogramming in merlin-deficient Schwann cells and promotes cell survival.

Authors:  Jeanine C Pestoni; Stephani Klingeman Plati; Oliver D Valdivia Camacho; Marisa A Fuse; Maria Onatunde; Nicklaus A Sparrow; Matthias A Karajannis; Cristina Fernández-Valle; Maria Clara Franco
Journal:  J Biol Chem       Date:  2019-06-06       Impact factor: 5.157

Review 5.  An update on the CNS manifestations of neurofibromatosis type 2.

Authors:  Shannon Coy; Rumana Rashid; Anat Stemmer-Rachamimov; Sandro Santagata
Journal:  Acta Neuropathol       Date:  2019-06-04       Impact factor: 17.088

Review 6.  Targeting mTOR and Metabolism in Cancer: Lessons and Innovations.

Authors:  Cedric Magaway; Eugene Kim; Estela Jacinto
Journal:  Cells       Date:  2019-12-06       Impact factor: 6.600

7.  UHPLC-HRMS-based serum lipisdomics reveals novel biomarkers to assist in the discrimination between colorectal adenoma and cancer.

Authors:  Hongwei Chen; Jiahao Zhang; Hailin Zhou; Yifan Zhu; Yunxiao Liang; Pingchuan Zhu; Qisong Zhang
Journal:  Front Oncol       Date:  2022-07-28       Impact factor: 5.738

8.  A new concept in NF2 pharmacotherapy: targeting fatty acid synthesis.

Authors:  Dina S Stepanova; Lanita Braun; Jonathan Chernoff
Journal:  Oncoscience       Date:  2018-06-23

9.  Serum untargeted lipidomics by UHPLC-ESI-HRMS aids the biomarker discovery of colorectal adenoma.

Authors:  Hailin Zhou; Yanying Nong; Yifan Zhu; Yunxiao Liang; Jiahao Zhang; Hongwei Chen; Pingchuan Zhu; Qisong Zhang
Journal:  BMC Cancer       Date:  2022-03-24       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.